Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Fluorine-18-MK 6240 (Primary) ; Florbetapir F 18
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Invicro; Molecular NeuroImaging
- 31 Aug 2018 Biomarkers information updated
- 09 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 09 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.